274 related articles for article (PubMed ID: 35881279)
1. CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.
Chen ST; Wu JW
Curr Pain Headache Rep; 2022 Sep; 26(9):667-675. PubMed ID: 35881279
[TBL] [Abstract][Full Text] [Related]
2. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
3. CGRP pathway monoclonal antibodies for cluster headache.
Chan C; Goadsby PJ
Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
[TBL] [Abstract][Full Text] [Related]
4. Galcanezumab for the prevention of cluster headache.
Giani L; Proietti Cecchini A; Leone M
Expert Opin Biol Ther; 2020 Oct; 20(10):1133-1142. PubMed ID: 32702245
[TBL] [Abstract][Full Text] [Related]
5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
6. Drug profile: galcanezumab for prevention of cluster headache.
Mudugal D; Monteith TS
Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
[No Abstract] [Full Text] [Related]
7. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
Khan S; Olesen A; Ashina M
Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
[TBL] [Abstract][Full Text] [Related]
8. [Galcanezumab for episodic and chronic cluster headache].
Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
[TBL] [Abstract][Full Text] [Related]
9. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series.
Iannone LF; Fattori D; Geppetti P; De Cesaris F
Neurol Sci; 2022 Jan; 43(1):697-703. PubMed ID: 34586542
[TBL] [Abstract][Full Text] [Related]
10. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
11. Anti-CGRP in cluster headache therapy.
Giani L; Proietti Cecchini A; Leone M
Neurol Sci; 2019 May; 40(Suppl 1):129-135. PubMed ID: 30820761
[TBL] [Abstract][Full Text] [Related]
12. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
13. Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases.
Kashiwagi K; Katsuki M; Kawamura S; Tachikawa S; Ono A; Koh A
Neurol Int; 2023 Feb; 15(1):318-324. PubMed ID: 36976663
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature.
Medrea I; Christie S; Tepper SJ; Thavorn K; Hutton B
Headache; 2022 Mar; 62(3):329-362. PubMed ID: 35315067
[TBL] [Abstract][Full Text] [Related]
15. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
Ossipov MH; Raffa RB; Pergolizzi JV
Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
Schuster NM; Rapoport AM
Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
[TBL] [Abstract][Full Text] [Related]
17. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
19. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
Scott LJ
Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
[TBL] [Abstract][Full Text] [Related]
20. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
